Vincristine sulfate salt is primarily used in the treatment of various types of cancer. It is a key component in chemotherapy regimens for leukemia, particularly acute lymphocytic leukemia (ALL), as well as Hodgkin's and non-Hodgkin's lymphomas. Additionally, it is effective against solid tumors such as Wilms' tumor, neuroblastoma, and rhabdomyosarcoma. The compound works by inhibiting the formation of microtubules, which are essential for cell division, thereby preventing the proliferation of cancer cells. It is often administered intravenously and is commonly used in combination with other chemotherapeutic agents to enhance its efficacy and reduce the risk of resistance. Due to its potent antineoplastic properties, it plays a critical role in both pediatric and adult oncology. However, its use requires careful monitoring due to potential side effects, such as neurotoxicity, which can manifest as peripheral neuropathy including numbness or muscle weakness.